{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:38:27Z","timestamp":1790883507327,"version":"4.1.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Non-alcoholic fatty liver disease (NAFLD) refers to the presence of hepatic steatosis (accumulation of fat in the liver to over 5% of its weight) in the absence of secondary causes of fat accumulation in the liver such as excessive alcohol use. NAFLD is divided into two types: non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH). Therefore, in this clinical guideline, we sought to determine general and important policies for this disease and modify its managment approaches. We adapted this guideline for the management of NAFLD in Isfahan Province. This guideline was developed by clinical appraisal and review of the evidence, available clinical guidelines, and in consultation with members of the Isfahan Chamber of the Iranian Association of Gastroenterology and Hepatology. Biopsy is recommended as the most reliable method (gold standard) to diagnose steatohepatitis and fibrosis in patients with NAFLD. NAFLD fibrosis score (NFS) and fibrosis-4 (FIB-4) are recommended as the test with the highest predictive value for advanced fibrosis in patients with NAFLD compared to other serologic tests. Among the noninvasive methods used to assess liver fibrosis, transient elastography (TE) is preferable to other methods.<\/jats:p>","DOI":"10.4103\/ijpvm.ijpvm_284_22","type":"journal-article","created":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T05:00:09Z","timestamp":1722834009000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Adaptation of Clinical Practice Guideline for Assessment of Liver Fibrosis in Patients with Non Alcoholic Fatty Liver Disease in Isfahan Province"],"prefix":"10.4103","volume":"15","author":[{"given":"Sayed Mohammad","family":"Hosseeini","sequence":"first","affiliation":[{"name":"Isfahan Gastroenterology and Hepatology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Jafari","sequence":"additional","affiliation":[{"name":"Isfahan Gastroenterology and Hepatology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzieh","family":"Tahmasebi","sequence":"additional","affiliation":[{"name":"Clinical Informationist Research Group, Health Information Technology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Payman","family":"Adibi","sequence":"additional","affiliation":[{"name":"Integrative Functional Gastroenterology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,5]]},"reference":[{"key":"R1-20240830","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1053\/j.gastro.2017.03.017","article-title":"American Gastroenterological Association Institute guideline on the role of elastography in the evaluation of liver fibrosis","volume":"152","author":"Lim","year":"2017","journal-title":"Gastroenterology"},{"key":"R2-20240830","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"R3-20240830","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/MCG.0000000000000116","article-title":"World Gastroenterology Organisation global guidelines: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"48","author":"LaBrecque","year":"2014","journal-title":"J Clin Gastroenterol"},{"key":"R4-20240830","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s00535-015-1050-7","article-title":"Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"50","author":"Watanabe","year":"2015","journal-title":"J Gastroenterol"},{"key":"R5-20240830","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s00125-016-3910-y","article-title":"EASL\u2013EASD\u2013EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease: Is universal screening appropriate?","volume":"59","author":"Byrne","year":"2016","journal-title":"Diabetologia"},{"key":"R8-20240830","doi-asserted-by":"crossref","first-page":"e1000094","DOI":"10.1371\/journal.pmed.1000094","article-title":"The GRADE system for rating clinical guidelines","volume":"6","author":"Kavanagh","year":"2009","journal-title":"PLoS Med"},{"key":"R9-20240830","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/jgh.13857","article-title":"Asia\u2013Pacific working party on non-alcoholic fatty liver disease guidelines 2017\u2014Part 1: Definition, risk factors and assessment","volume":"33","author":"Wong","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"key":"R10-20240830","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000443344","article-title":"EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease","volume":"9","year":"2016","journal-title":"Obesity Facts"},{"key":"R11-20240830","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.3748\/wjg.v24.i30.3361","article-title":"Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis","volume":"24","author":"Leoni","year":"2018","journal-title":"World J Gastroenterol"},{"key":"R12-20240830","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.dld.2017.01.147","article-title":"AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions","volume":"49","author":"Lonardo","year":"2017","journal-title":"Dig Liver Dis"},{"key":"R13-20240830","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/liv.14669","article-title":"Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: A systematic review","volume":"41","author":"Lee","year":"2021","journal-title":"Liver Int"},{"key":"R14-20240830","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis\u20132021 update","volume":"75","author":"Berzigotti","year":"2021","journal-title":"J Hepatol"},{"key":"R15-20240830","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"R16-20240830","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/MCG.0000000000000116","article-title":"World Gastroenterology Organisation global guidelines: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"48","author":"LaBrecque","year":"2014","journal-title":"J Clin Gastroenterol"},{"key":"R17-20240830","first-page":"33","article-title":"Noninvasive measures of liver fibrosis and severity of liver disease","volume":"12","author":"Lucero","year":"2016","journal-title":"Gastroenterol Hepatol"},{"key":"R18-20240830","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1097\/MPG.0b013e318252a13f","article-title":"Diagnosis of nonalcoholic fatty liver disease in children and adolescents: Position paper of the ESPGHAN Hepatology Committee","volume":"54","author":"Vajro","year":"2012","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R19-20240830","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jhep.2006.12.013","article-title":"Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C","volume":"46","author":"Leroy","year":"2007","journal-title":"J Hepatol"},{"key":"R20-20240830","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/hep.22576","article-title":"Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease","volume":"49","author":"Naveau","year":"2009","journal-title":"Hepatology"},{"key":"R21-20240830","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.cgh.2009.01.010","article-title":"Validation of hepascore, compared with simple indices of fibrosis, in patients with chronic hepatitis C virus infection in United States","volume":"7","author":"Becker","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R22-20240830","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1111\/apt.16664","article-title":"Randomised clinical trial: A phase 2 double-blind study of namodenoson in non-alcoholic fatty liver disease and steatohepatitis","volume":"54","author":"Safadi","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"R23-20240830","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.dld.2010.01.021","article-title":"Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease: A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee","volume":"42","author":"Loria","year":"2010","journal-title":"Dig Liver Dis"},{"key":"R24-20240830","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1055\/s-0043-103952","article-title":"EFSUMB guidelines and recommendations on the clinical use of liver ultrasound elastography, update 2017 (long version)","volume":"38","author":"Dietrich","year":"2017","journal-title":"Ultraschall Med"},{"key":"R25-20240830","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1148\/radiol.2015150619","article-title":"Elastography assessment of liver fibrosis: Society of radiologists in ultrasound consensus conference statement","volume":"276","author":"Barr","year":"2015","journal-title":"Radiology"},{"key":"R26-20240830","doi-asserted-by":"crossref","first-page":"e733","DOI":"10.1055\/a-1880-2388","article-title":"Updated S2k clinical practice guideline on non-alcoholic fatty liver disease (NAFLD) issued by the German society of gastroenterology, digestive and metabolic diseases (DGVS)\u2013April 2022\u2013 AWMF registration No.: 021\u2013025","volume":"60","author":"Tacke","year":"2022","journal-title":"Z Gastroenterol"},{"key":"R27-20240830","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.ultrasmedbio.2015.03.007","article-title":"WFUMB guidelines and recommendations for clinical use of ultrasound elastography: Part 3: Liver","volume":"41","author":"Ferraioli","year":"2015","journal-title":"Ultrasound Med Biol"},{"key":"R28-20240830","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/apt.13488","article-title":"Systematic review with meta-analysis: The diagnostic accuracy of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B","volume":"43","author":"Li","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"R29-20240830","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/hep.22742","article-title":"Liver biopsy","volume":"49","author":"Rockey","year":"2009","journal-title":"Hepatology"},{"key":"R30-20240830","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1136\/gutjnl-2020-321299","article-title":"Guidelines on the use of liver biopsy in clinical practice from the British Society of Gastroenterology, the Royal College of Radiologists and the Royal College of Pathology","volume":"69","author":"Neuberger","year":"2020","journal-title":"Gut"},{"key":"R31-20240830","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1136\/jcp.2008.062349","article-title":"Histological scoring of fibrosis and activity in HIV-chronic hepatitis B related liver disease: Performance of the METAVIR score assessed on virtual slides","volume":"62","author":"Wendum","year":"2009","journal-title":"J Clin Pathol"}],"container-title":["International Journal of Preventive Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijpvm.ijpvm_284_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:00:37Z","timestamp":1787839237000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijpvm.ijpvm_284_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":29,"URL":"https:\/\/doi.org\/10.4103\/ijpvm.ijpvm_284_22","relation":{},"ISSN":["2008-7802","2008-8213"],"issn-type":[{"value":"2008-7802","type":"print"},{"value":"2008-8213","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"2022-08-21","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}